RBD-HR nanoparticle vaccine
An experimental COVID-19 vaccine.
General information
RBD-HR nanoparticle vaccine is composed of Helicobacter pylori non-haem ferritin self-assembled nanoparticles, each with 24 copies of covalently conjugated either receptor binding domains or heptad repeats (of SARS-CoV-2 Spike protein) in 7:3 molar ratio (Ma et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
Spike protein Biophysical assay Protein factor Animal model In vitro Mixed substance |
in vitro biophysical assay; hACE2-HeLa cells; BALB/c mice; hACE2-mice; rhesus macaques | 22.55 | The nanoparticles bound to ACE2 with similar affinity as RBD monomers in vitro. The elicited murine antibodies significantly inhibited RBD-ACE2 interaction. The nanoparticle vaccine produced stronger anti-RBD humoral IgG response in BALB/c mice than in the case of monomeric RBD vaccination. Anti-HR response was approximately the same as upon RBD-HR fusion monomer vaccination. The antibody titres peaked as early as two weeks post priming. The nanoparticles elicited strong neutralizing antibody responses (against both SARS-CoV-2 live- and pseudoviruses). Strong T and B cell responses were detected in immunized BALB/c mice. The observed stronger responses to nanoparticles compared to the corresponding monomeric antigens might have been the result of stronger capture by dendritic cells and macrophages. The nanoparticles protected hACE2-mice from SARS-CoV-2 infection without signs of antibody-dependent enhancement and exerted robust immunogenicity in rhesus macaques. |
Nov/25/2020 |
